Main Article Content

Amira Shahid Sheikh
Amal Malik
Dr. Masooda Fatima
Dr. Coenrad Adolph Groenewald
Dr. Elma Sibonghanoy Groenewald
Dr. ShamsUllah


Neurological Diseases, Nutritional Therapy, Side Effects.


Introduction: Neurological diseases resulting from nervous system injuries can profoundly impact nutritional status and compromise physical and cognitive capabilities necessary for adequate dietary intake. This study focuses on exploring primary nutritional therapies for neurological illnesses.

Methods: An integrative literature review was conducted utilizing databases including PePSIC, Medline, and LILACS. A comprehensive search strategy encompassed cross-referencing descriptors such as neuropathies, nutritional therapy, efficacy, and side effects in both Pakistan and China. The search period spanned from January to July 2023. Following the application of inclusion criteria, 175 relevant items were identified.

Results: While traditional medical interventions for neurological conditions primarily involve pharmacotherapy, food therapy has shown promise in enhancing clinical outcomes and alleviating symptoms in certain diseases. Nutritional interventions have been particularly effective in improving the prognosis of adrenoleukodystrophy and ameliorating symptoms of Wernicke-Korsakoff syndrome and epilepsy. As such, patients afflicted with these conditions stand to benefit significantly from tailored dietary interventions.

Conclusion: Nutritional therapy presents a valuable adjunctive approach in managing neurological diseases, offering opportunities to enhance patient outcomes and alleviate symptoms where traditional medical interventions may fall short. Incorporating dietary interventions into comprehensive treatment plans for neurological disorders is imperative for optimizing patient care and recovery.

Abstract 186 | PDF Downloads 67


1. Ayyubova, G. (2024). Apoe4 is A risk factor and potential therapeutic target for Alzheimer's disease. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders).
2. Belov, V., Erwin-Grabner, T., Aghajani, M., Aleman, A., Amod, A. R., Basgoze, Z., . . . Ching, C. R. (2024). Multi-site benchmark classification of major depressive disorder using machine learning on cortical and subcortical measures. Scientific Reports, 14(1), 1084.
3. Bhatia, D., Paul, S., Acharjee, T., & Ramachairy, S. S. (2024). Biosensors and their widespread impact on human health. Sensors International, 5, 100257.
4. Bi, Y., & Uludag, K. (2024). Effects of Genetic Counseling on Reducing Prenatal Stress and Autism Rates in the Asia-Pacific Region Emerging Technologies for Health Literacy and Medical Practice (pp. 341-363): IGI Global.
5. Christogianni, A. (2025). The Benefits of Continuous Health Data Monitoring in Cardiovascular Diseases and Dementia Encyclopedia of Information Science and Technology, Sixth Edition (pp. 1-22): IGI Global.
6. De Marchi, F., Vignaroli, F., Mazzini, L., Comi, C., & Tondo, G. (2024). New Insights into the Relationship between Nutrition and Neuroinflammation in Alzheimer's Disease: Preventive and Therapeutic Perspectives. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders).
7. Dias-Carvalho, A., Sá, S. I., Carvalho, F., Fernandes, E., & Costa, V. M. (2024). Inflammation is a common link to progressive neurological diseases. Archives of toxicology, 98(1), 95-119.
8. Foley, C., Kirkby, A., & Eccles, F. J. (2024). A meta-ethnographic synthesis of the experiences of stigma amongst people with functional neurological disorder. Disability and Rehabilitation, 46(1), 1-12.
9. Golpour-Hamedani, S., Pourmasoumi, M., Zarifi, S. H., Askari, G., Jamialahmadi, T., Bagherniya, M., & Sahebkar, A. (2024). Therapeutic effects of saffron and its components on neurodegenerative diseases. Heliyon.
10. Gombošová, L., Deptová, J., Jochmanová, I., Svoreňová, T., Veseliny, E., Zakuciová, M., . . . Ostrožovičová, M. (2024). Endoscopic Complications Are More Frequent in Levodopa–Carbidopa Intestinal Gel Treatment via JET-PEG in Parkinson’s Disease Patients Compared to Nutritional PEG in Non-Parkinson’s Disease Patients. Journal of Clinical Medicine, 13(3), 703.
11. Goswami, D., Anuradha, U., Angati, A., Kumari, N., & Singh, R. K. (2024). Pharmacological and pathological relevance of S100 proteins in neurological disorders. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders).
12. Hernandez-Leon, A., Escamilla-Orozco, R. I., Tabal-Robles, A. R., Martínez-Vargas, D., Romero-Bautista, L., Escamilla-Soto, G., . . . González-Trujano, M. E. (2024). Antidepressant-and anxiolytic-like activities and acute toxicity evaluation of the Psilocybe cubensis mushroom in experimental models in mice. Journal of Ethnopharmacology, 320, 117415.
13. Hirjak, D., Brandt, G. A., Peretzke, R., Fritze, S., Meyer-Lindenberg, A., Maier-Hein, K. H., & Neher, P. F. (2024). Microstructural white matter biomarkers of symptom severity and therapy outcome in catatonia: Rationale, study design and preliminary clinical data of the white CAT study. Schizophrenia Research, 263, 160-168.
14. Holroyd, K. B., & Berkowitz, A. L. (2024). Metabolic and toxic myelopathies. CONTINUUM: Lifelong Learning in Neurology, 30(1), 199-223.
15. Jha, P., Dangi, N., & Sharma, S. (2024). Probiotics Show Promise as a Novel Natural Treatment for Neurological Disorders. Current Pharmaceutical Biotechnology.
16. Kakaei, M., Rehman, F. U., & Fazeli, F. (2024). The effect of chickpeas metabolites on human diseases and the application of their valuable nutritional compounds suitable for human consumption. Cellular, Molecular and Biomedical Reports, 4(1), 30-42.
17. Khairnar, S. J., Ahire, E. D., Jagtap, M. R., Surana, K. R., Kshirsagar, S. J., & Keservani, R. K. (2024). Nutritional Properties of Polyphenols Advances in Flavonoids for Human Health and Prevention of Diseases (pp. 1-22): Apple Academic Press.
18. Kirkbride, J. B., Anglin, D. M., Colman, I., Dykxhoorn, J., Jones, P. B., Patalay, P., . . . Wright, T. (2024). The social determinants of mental health and disorder: evidence, prevention and recommendations. World psychiatry, 23(1), 58.
19. Krishnamoorthy, N. K., Kalyan, M., Hediyal, T. A., Anand, N., Kendaganna, P. H., Pendyala, G., . . . Sakharkar, M. K. (2024). Role of the Gut Bacteria-Derived Metabolite Phenylacetylglutamine in Health and Diseases. ACS omega.
20. Last, B. S., Mirhashem, R., & Yang, Y. (2024). From plan to practice: A qualitative study of public mental health therapists' session-planning practices. Psychological Services.
21. Marques, T. M., Ganda-Mall, J. P., Forsgård, R., Wall, R., Brummer, R. J., & de Vos, W. M. (2024). Correlating the gut microbiome to health and disease The gut-brain axis (pp. 1-36): Elsevier.
22. Martino Cinnera, A., Picerno, P., Bisirri, A., Koch, G., Morone, G., & Vannozzi, G. (2024). Upper limb assessment with inertial measurement units according to the international classification of functioning in stroke: a systematic review and correlation meta-analysis. Topics in Stroke Rehabilitation, 31(1), 66-85.
23. Mattsson-Carlgren, N., Collij, L. E., Stomrud, E., Binette, A. P., Ossenkoppele, R., Smith, R., . . . Strandberg, O. (2024). Plasma biomarker strategy for selecting patients with Alzheimer's disease for anti-amyloid immunotherapies. JAMA neurology, 81(1), 69-78.
24. Mazzucca, C. B., Cappellano, G., & Chiocchetti, A. (2024). Nutrition, Immunity and Aging: Current Scenario and Future Perspectives in Neurodegenerative Diseases. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders).
25. NEHIR, A., UCLER, N., & GEYIK, M. (2024). Neural tube defects. HEALTH & SCIENCE 2023-IV, 101.
26. Probst, Y., Luscombe, M., Hilfischer, M., Guan, V., & Houston, L. (2024). Exploring factors to the interpretation of targeted nutrition messages for people living with multiple sclerosis. Patient Education and Counseling, 119, 108039.
27. Reznik, E. (2024). A Review of a Ketogenic Diet In the Treatment of Autism Spectrum Disorder.
28. Roche, H. M., Macdonald, I. A., Schols, A., & Lanham-New, S. A. (2024). Nutrition and metabolism: John Wiley & Sons.
29. Romano, A., Primiano, G., Antonini, G., Ceccanti, M., Fenu, S., Forcina, F., . . . Manganelli, F. (2024). Serum neurofilament light chain: a promising early diagnostic biomarker for hereditary transthyretin amyloidosis? European Journal of Neurology, 31(1), e16070.
30. Schläppi, K., Reber, E., Schönenberger, K. A., Stanga, Z., & Kurmann, S. (2024). The influence of patients' nutritional risk, nutritional status, and energy density in MEDPass versus conventional administration of oral dietary supplements–A secondary analysis of a randomized controlled trial. The Journal of nutrition, health, and aging, 28(3), 100170.
31. Schulz, M.-A., Bzdok, D., Haufe, S., Haynes, J.-D., & Ritter, K. (2024). Performance reserves in brain-imaging-based phenotype prediction. Cell Reports, 43(1).
32. Sharma, M., Molina, C. A., Toyoda, K., Bereczki, D., Bangdiwala, S. I., Kasner, S. E., . . . Czlonkowska, A. (2024). Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomized, double-blind, placebo-controlled, dose-finding trial. The Lancet Neurology, 23(1), 46-59.
33. Silakari, P., Yadav, A., Arora, A., Arora, A., Gulsheen, G., Kaur, P., & Sahu, S. K. (2024). Investigating Holistic Natural Strategies for The Management of Huntington's Disease. Paper presented at the BIO Web of Conferences.
34. Singh, S., Sangam, S. R., & Rajagopal, S. (2030). ROLE OF DIETARY AMINO ACIDS ON PARKINSON'S DISEASE. Food and Parkinson's disease, 1.
35. Spencer, C. M., Keilholtz, B. M., Palmer, M., & Vail, S. L. (2024). Mental and physical health correlates for emotional, intimate partner violence perpetration and victimization: A meta-analysis. Trauma, Violence, & Abuse, 25(1), 41-53.
36. Taoka, T., Ito, R., Nakamichi, R., Nakane, T., Kawai, H., & Naganawa, S. (2024). Interstitial fluidopathy of the central nervous system: an umbrella term for disorders with impaired neurofluid dynamics. Magnetic Resonance in Medical Sciences, 23(1), 1-13.
37. Tryfonos, C., Chrysafi, M., Vadikolias, K., Berberoglou, L., Vorvolakos, T., Dimoliani, S., . . . Giaginis, C. (2024). Nutritional interventional studies in patients with multiple sclerosis: a scoping review of the current clinical evidence. Journal of Neurology, 1-35.
38. Walaszek, M., Kachlik, Z., & Cubała, W. J. (2024). Low-carbohydrate diet as a nutritional intervention in a major depression disorder: focus on relapse prevention. Nutritional Neuroscience, 1-14.
39. Wang, X., Cheng, X., Liu, H., Mu, X., & Zheng, H. (2024). Food nutrition and toxicology targeting specific organs in the era of single-cell sequencing. Food Science and Human Wellness, 13(1), 75-89.
40. Xabibullayevich, S. S., Temirpulotovich, T. B., Sherboyevich, H. B., & Nematillayevna, S. D. (2024). Clinical-psychopathological and pathopsychological analysis of depressive disorders in late life. Amaliy va tibbiyot fanlari ilmiy jurnali, 3(1), 78-84.
41. Xiong, Y., Mahmood, A., & Chopp, M. (2024). Mesenchymal stem cell-derived extracellular vesicles as a cell-free therapy for traumatic brain injury via neuroprotection and neurorestoration. Neural Regeneration Research, 19(1), 49-54.
42. Yılmaz, M., Atuk Kahraman, T., Kurtbeyoğlu, E., Konyalıgil Öztürk, N., & Gültekin, M. (2024). The evaluation of the nutritional status in Parkinson's disease: geriatric dietary risk index comparison with mini nutritional assessment questionnaire. Nutritional Neuroscience, 27(1), 66-73.
43. Zamanian, M. Y., Terefe, E. M., Taheri, N., Kujawska, M., Tork, Y. J., Abdelbasset, W. K., . . . Alesaeidi, S. (2024). Neuroprotective and anti-inflammatory effects of pioglitazone on Parkinson's disease: A comprehensive narrative review of clinical and experimental findings. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders).

Most read articles by the same author(s)